Patents Assigned to GI INNOVATION, INC.
-
Publication number: 20240058420Abstract: A pharmaceutical composition for treating cancer, containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent. A fusion protein containing a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein containing an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.Type: ApplicationFiled: November 1, 2023Publication date: February 22, 2024Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Su Youn NAM, Young Jun KOH
-
Patent number: 11857601Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.Type: GrantFiled: March 18, 2021Date of Patent: January 2, 2024Assignee: GI INNOVATION, INC.Inventors: Myung Ho Jang, Su Youn Nam, Young Jun Koh
-
Publication number: 20230257459Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein dimer including an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor is disclosed. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, the fusion protein dimer and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.Type: ApplicationFiled: March 1, 2023Publication date: August 17, 2023Applicant: GI INNOVATION, INC.Inventors: Myoung Ho JANG, Su Youn NAM, Young Jun KOH, Young-Gyu CHO
-
Publication number: 20230233680Abstract: A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.Type: ApplicationFiled: June 1, 2021Publication date: July 27, 2023Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Su Youn NAM, Young Jun KOH
-
Publication number: 20230190876Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.Type: ApplicationFiled: March 18, 2021Publication date: June 22, 2023Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Su Youn NAM, Young Jun KOH
-
Publication number: 20230139890Abstract: The present invention relates to a fusion protein dimer comprising a modified IL-2 protein and a CD80 protein fragment or a variant thereof. The fusion protein comprising an IL-2 protein and a CD80 protein fragment or a variant thereof can not only activate immune cells owing to IL-2, but also effectively regulate Treg cells owing to CD80. Therefore, the fusion protein can efficiently attack cancer cells, and thus can be usefully employed for treatment of cancer or an infectious disease.Type: ApplicationFiled: March 18, 2021Publication date: May 4, 2023Applicant: GI INNOVATION, INC.Inventors: Myoung Ho JANG, Jae Chan PARK
-
Patent number: 11639383Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.Type: GrantFiled: November 27, 2020Date of Patent: May 2, 2023Assignee: GI INNOVATION, INC.Inventors: Myoung Ho Jang, Su Youn Nam, Young Jun Koh, Young-Gyu Cho
-
Publication number: 20230125871Abstract: The present invention relates to a pharmaceutical formulation with enhanced stability of a fusion protein dimer comprising a modified IL-2 protein and a CD80 protein. The fusion protein dimer comprising an IL-2 protein and a CD80 protein can not only activate immune cells owing to IL-2, but also effectively regulate Treg cells owing to CD80. When the formulation according to the present invention is applied to a fusion protein dimer comprising an IL-2 protein and a CD80 protein, the stability of the fusion protein dimer is significantly increased, and it can be used as a liquid formulation. Accordingly, the commercial applicability of the fusion protein dimer can be increased.Type: ApplicationFiled: March 17, 2021Publication date: April 27, 2023Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Young Min OH, Heonchang LIM
-
Publication number: 20230104217Abstract: Provided is a fusion protein comprising IL-2 protein and CD80 protein, a fusion protein having a high content of sialic acid, and a pharmaceutical composition containing same. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. In addition, the fusion protein having a high content of sialic acid can proliferate immune cells, such as lymphocytes including CD8+ T cells and natural killer cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.Type: ApplicationFiled: September 20, 2022Publication date: April 6, 2023Applicant: GI INNOVATION, INC.Inventor: Myung Ho JANG
-
Publication number: 20220403019Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.Type: ApplicationFiled: November 27, 2020Publication date: December 22, 2022Applicant: GI INNOVATION, INC.Inventors: Myoung Ho JANG, Su Youn NAM, Young Jun KOH, Young-Gyu CHO
-
Publication number: 20220389070Abstract: Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.Type: ApplicationFiled: August 1, 2022Publication date: December 8, 2022Applicant: GI INNOVATION, INC.Inventor: Myung Ho JANG
-
Publication number: 20220380781Abstract: Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.Type: ApplicationFiled: August 1, 2022Publication date: December 1, 2022Applicant: Gi Innovation, Inc.Inventor: Myung Ho JANG
-
Patent number: 11492384Abstract: Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein comprising CD80 fragment, immunoglobulin Fe, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition comprising the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.Type: GrantFiled: September 16, 2019Date of Patent: November 8, 2022Assignee: GI INNOVATION, INC.Inventor: Myung Ho Jang
-
Publication number: 20220257693Abstract: A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.Type: ApplicationFiled: July 7, 2020Publication date: August 18, 2022Applicant: GI INNOVATION, INC.Inventors: Myoung Ho JANG, Bo-Gie YANG, Kyungwha LEE
-
Publication number: 20200369740Abstract: Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein comprising CD80 fragment, immunoglobulin Fe, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition comprising the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.Type: ApplicationFiled: September 16, 2019Publication date: November 26, 2020Applicant: GI INNOVATION, INC.Inventor: Myung Ho JANG